Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing ...

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available ...

MiRus announced that it launched a U.S. multi-center early feasibility study for its Siegel transcatheter heart valve (THV).

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, presented results from an expanded cohort of 500 patients in the ALIGN-AR Pivotal Trial ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

Discover why suture-based closure may be safer for TAVI patients. Learn more about this large registry analysis.